Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 199-205

  Vrooman, Lynda M ^a,b   Supko, Jeffrey G ^c   Neuberg, Donna S ^a   Asselin, Barbara L ^d   Athale, Uma H ^e   Clavell, Luis ^f   Kelly, Kara M ^g   Laverdière, Caroline ^h   Michon, Bruno ⁱ   Schorin, Marshall ^j   Cohen, Harvey J ^k   Sallan, Stephen E ^a,b   Silverman, Lewis B ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f San Jorge Children's Hospital   (Puerto Rico)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF MONTREAL   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

^j INOVA FAIRFAX HOSPITAL   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Asparaginase; Childhood; Erwinia; Leukemia

Indexed keywords

ASPARAGINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ERWINIA; ESCHERICHIA COLI; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOSIS; URTICARIA;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; ERWINIA; ESCHERICHIA COLI; HUMANS; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL ANALYSIS;

EID: 74849106175     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22225     Document Type: Article

References (34)

1. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218.
2. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-1532.
3. Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794-799.
4. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-1383.
5. Billett AL, Carls A, Gelber RD, et al. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992;70:201-206.
6. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer 1976;38:1843-1846.
7. Wang B, RellingMV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003;17: 1583-1588.
8. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217-226.
9. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786.
10. Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: A Children's Oncology Group Study. J Pediatr Hematol Oncol 2007;29:627-632.
11. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 1972;30:376-381.
12. King OY,Wilbur JR, Mumford DM, et al. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer 1974;33:611-614.
13. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.
14. Waghorne C, Stevenson KE, Neuberg DS, et al. Individualized versus fixed dosing of L-asparaginase during intensification therapy in children treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 00-001. J Clin Oncol 2007;25:abstract 2000.
15. Vrooman L, Neuberg D, O'Brien J, et al. Increased risk of skeletal toxicity and infection in children 10 years or older treated for acute lymphoblastic leukemia (all) with dexamethasone: Results from the DFCI ALL Consortium. Blood 2007;110:abstract 849.
16. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium. Cancer 1997;80:2285-2295.
17. Silverman LB, Gelber RD, Young ML, et al. Induction failure in acute lymphoblastic leukemia of childhood. Cancer 1999;85: 1395-1404.
18. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32:1544-1550.
19. Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11:189-193.
20. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675-681.
21. Avramis VI, Sencer S, Periclou AP, et al.Arandomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002;99:1986-1994.
22. Berg SL, Balis FM, McCully CL, et al. Pharmacokinetics of PEGL-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemother Pharmacol 1993;32:310-314.
23. Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558.
24. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group Phase 3 trial. Blood 2002;99:2734-2739.
25. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-5607.
26. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527-1533.
27. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004;18:1072-1077.
28. Zalewska-Szewczyk B, AndrzejewskiW, Bodalski J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:600-602.
29. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group Study. Leukemia 1999;13:335-342.
30. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-663.
31. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12:740-747.
32. LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 2002;20:237-246.
33. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104:313-320.
34. Albertsen BK, Schroder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: Pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115:983-990.